The Top 5 Biosimilar Articles for the Week of January 18
Here are the top 5 biosimilar articles for the week of January 18, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of January 18, 2021.
Number 5: Results were inconclusive in a study of hypertension and proteinuria in 75 patients treated with bevacizumab reference vs biosimilar products, investigators reported at the ASCO Gastrointestinal Cancers Symposium 2021.
Number 4: Switching patients with inflammatory bowel disease (IBD) from the CT-P13 infliximab biosimilar to the SB2 infliximab biosimilar appears to be safe and effective whether 1 or more switches between biosimilars and the originator product were involved, investigators concluded in a retrospective study.
Number 3: Investigators have demonstrated that initial uptake of the first bevacizumab biosimilar (Mvasi, Amgen) in the United States was strongest for patients receiving treatment for metastatic colorectal cancer (mCRC).
Number 2: Sonia T. Oskouei, PharmD, BCMAS, DPLA, wrote an opinion piece on why ophthalmology biosimilars are a therapeutic area to watch in 2021.
Number 1: The Center for Biosimilars® reported on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.
To read all of these articles and more, visit centerforbiosimilars.com.
Recent Findings Highlight Need for Policy Changes for Biosimilars, Follow-on Biologics
